Jared Isaacman made a small fortune training fighter pilots but his wealth soared this summer when he took his payments processing business public amid the pandemic.
Category: biotech/medical
One of the most remarkable recent advances in biomedical research has been the development of highly targeted gene-editing methods such as CRISPR that can add, remove, or change a gene within a cell with great precision. The method is already being tested or used for the treatment of patients with sickle cell anemia and cancers such as multiple myeloma and liposarcoma, and today, its creators Emmanuelle Charpentier and Jennifer Doudna received the Nobel Prize in chemistry.
While gene editing is remarkably precise in finding and altering genes, there is still no way to target treatment to specific locations in the body. The treatments tested so far involve removing blood stem cells or immune system T cells from the body to modify them, and then infusing them back into a patient to repopulate the bloodstream or reconstitute an immune response—an expensive and time-consuming process.
Building on the accomplishments of Charpentier and Doudna, Tufts researchers have for the first time devised a way to directly deliver gene-editing packages efficiently across the blood brain barrier and into specific regions of the brain, into immune system cells, or to specific tissues and organs in mouse models. These applications could open up an entirely new line of strategy in the treatment of neurological conditions, as well as cancer, infectious disease, and autoimmune diseases.
A team of researchers from University Hospital Zurich and the University of Zurich, the Swiss Federal Institute of Technology and biotechnology company Philochem, has found fusing cytokines with antibodies to be an effective treatment for glioblastoma in mice. In their paper published in the journal Science Translational Medicine, the group describes their technique and how well it worked when tested with mouse models.
Glioblastoma is a type of cancerous brain tumor that is notoriously difficult to treat. Surgery to remove it is difficult and fraught with side effects, and drugs have little impact. In recent years, researchers have tried using drugs that alert the immune system to the presence of the tumor but they have not worked as hoped, either. In this new effort, the researchers tried another approach—fusing cytokines with antibodies as a way to attack the tumor. The hope was that together, the two would incite the immune system to attack the tumor more strongly and hopefully get rid of it.
Cytokines are small protein cells secreted by the immune system. Their usual job is to send signals to other cells in the immune system. And antibodies are Y-shaped proteins produced by plasma cells, the workhorses of the immune system that attack viruses and bacteria. In this new effort, the researchers fused L19 antibodies to cytokines. L19 was chosen because prior research has shown that it is able to seek out markers for glioblastoma. Fusing the two proteins together proved to be a more formidable therapeutic approach than using either alone. The resulting (L19TNF) immunocytokines were injected into mice with induced glioblastoma and were then monitored to determine their impact on the brain tumors.
Once a leading cause of death for children across the western world, scarlet fever was nearly eradicated thanks to 20th century medicine. But fresh outbreaks in the UK and North East Asia over recent years suggest we’ve still got a long way to go.
Just why we’re experiencing a resurgence of the deadly pathogen is a mystery. A new study has uncovered clues in the genome of one of the bacterial strains responsible, showing just how complex the family tree of infectious diseases can be.
The species behind the illness is group A strep, or Streptococcus pyogenes; a ball-shaped microbe that can churn out toxic compounds called superantigens, capable of wreaking havoc inside the body. Especially in children.
Perhaps in the future, gene editing may allow retinal regeneration in humans to reverse age-related vision deterioration.
Damage to the retina is the leading cause of blindness in humans, affecting millions of people around the world. Unfortunately, the retina is one of the few tissues we humans can’t grow back.
Unlike us, other animals such as zebrafish are able to regenerate this tissue that’s so crucial to our power of sight. We share 70 percent of our genes with these tiny little zebrafish, and scientists have just discovered some of the shared genes include the ones that grant zebrafish the ability to grow back their retinas.
“Regeneration seems to be the default status, and the loss of that ability happened at multiple points on the evolutionary tree,” said Johns Hopkins University neuroscientist Seth Blackshaw.
Vaccines could take years, and preventative drugs could help bridge the gap.
Though many people are pinning their hopes on a COVID-19 vaccine, another option is available: preventive treatment. At a Senate hearing this week, Anthony Fauci noted that a vaccine — which is probably months or years away — isn’t the only way to protect someone from a life-threatening virus.
These treatments could protect people against infection for a few weeks or months, said Fauci, the director of the National Institute of Allergy and Infectious Diseases. While most ongoing research studies are focused on finding treatments for people who are already sick with COVID-19, some researchers are looking to see if they can stop people who are at high risk from getting sick in the first place.
It’s a proven strategy: preventive drugs have been used for decades to help people protect themselves against malaria. More recently, they were a breakthrough in the fight against HIV. There’s no effective vaccine against HIV, but people can take a daily medication that reduces their risk of contracting it through sexual activity by 99 percent. The medication is a pre-exposure prophylactic, or PrEP — a drug used to prevent disease in people who haven’t yet been exposed to it.
The discovery is being used to make a drug for potential therapeutic and preventive use against COVID-19.
In this brief, at times controversial— even radical—volume. Dr. Ian C. Hale guides us through likely scenarios and gives us life-saving recommendations for effectively dealing with the next waves of the COVID-19 pandemic. This is a must read for public policy makers, medical professionals, and those mapping out their financial future in the post-corona world.
Although it’s clearly NOT the approach taken for ultracold vitrification of patients undergoing life extension cryonization. (ULTRA🥶COLD being the exact opposite of ULTRA-BLOODY-H🥵T, obviously!)
Still, given the vast number of scientific and engineering discoveries and creations born on the backs of unexpected results, accidental discoveries, and outright screw up, it might have very useful data that has practical applications that would never otherwise have even been considered.
Italian scientists found intact brain cells in a man who was killed during the eruption of Mount Vesuvius in 79 AD.
Selection of just two scientists will stir controversy, given patent fight over genome editor’s discovery.